The prospect of harnessing the microbiome to improve immunotherapeutic response in pancreatic cancer
S Rogers, A Charles, RM Thomas - Cancers, 2023 - mdpi.com
Simple Summary Pancreatic cancer is an insidious disease, often diagnosed late in its
course when curative treatments are moot, with a 5-year median overall survival of~ 12 …
course when curative treatments are moot, with a 5-year median overall survival of~ 12 …
Claudin 1, 4, 6 and 18 isoform 2 as targets for the treatment of cancer
M Katoh, M Katoh - International Journal of Molecular …, 2024 - spandidos-publications.com
The 24 claudin (CLDN) genes in the human genome encode 26 representative CLDN family
proteins. CLDNs are tetraspan-transmembrane proteins at tight junctions. Because several …
proteins. CLDNs are tetraspan-transmembrane proteins at tight junctions. Because several …
LIM domain only 7: a novel driver of immune evasion through regulatory T cell differentiation and chemotaxis in pancreatic ductal adenocarcinoma
S Dai, Y Peng, G Wang, C Chen, Q Chen… - Cell Death & …, 2024 - nature.com
With advancements in genomics and immunology, immunotherapy has emerged as a
revolutionary strategy for tumor treatment. However, pancreatic ductal adenocarcinoma …
revolutionary strategy for tumor treatment. However, pancreatic ductal adenocarcinoma …
ATR inhibition potentiates FOLFIRINOX cytotoxic effect in models of pancreatic ductal adenocarcinoma by remodelling the tumour microenvironment
M Bruciamacchie, V Garambois, N Vie… - British Journal of …, 2024 - nature.com
Background In pancreatic ductal adenocarcinoma (PDAC), the dense stroma rich in cancer-
associated fibroblasts (CAFs) and the immunosuppressive microenvironment confer …
associated fibroblasts (CAFs) and the immunosuppressive microenvironment confer …
CD64+ fibroblast-targeted vilanterol and a STING agonist augment CLDN18. 2 BiTEs efficacy against pancreatic cancer by reducing desmoplasia and enriching stem …
T Zhou, X Hou, J Yan, L Li, Y Xie, W Bai, W Jiang… - Gut, 2024 - gut.bmj.com
Objective The objective of this study is to improve the efficacy of CLDN18. 2/CD3 bispecific T-
cell engagers (BiTEs) as a promising immunotherapy against pancreatic ductal …
cell engagers (BiTEs) as a promising immunotherapy against pancreatic ductal …
Targeting Prostate Cancer Using Bispecific T-Cell Engagers against Prostate-Specific Membrane Antigen
G Das, J Ptacek, B Havlinova… - ACS Pharmacology & …, 2023 - ACS Publications
Prostate cancer (PCa) tops the list of cancer-related deaths in men worldwide. Prostate-
specific membrane antigen (PSMA) is currently the most prominent PCa biomarker, as its …
specific membrane antigen (PSMA) is currently the most prominent PCa biomarker, as its …
Pan-cancer analysis of CLDN18. 2 shed new insights on the targeted therapy of upper gastrointestinal tract cancers
J Wu, J Lu, Q Chen, H Chen, Y Zheng… - Frontiers in …, 2024 - frontiersin.org
Background CLDN18. 2 is a widely researched drug target. However, previous research has
primarily been based on immunohistochemistry results and focused on gastric cancer …
primarily been based on immunohistochemistry results and focused on gastric cancer …
DR30318, a novel tri-specific T cell engager for Claudin 18.2 positive cancers immunotherapy
Z Ma, Z Zhou, W Duan, G Yao, S Sheng, S Zong… - Cancer Immunology …, 2024 - Springer
Abstract Background Claudin 18.2 (CLDN18. 2) is a highly anticipated target for solid tumor
therapy, especially in advanced gastric carcinoma and pancreatic carcinoma. The T cell …
therapy, especially in advanced gastric carcinoma and pancreatic carcinoma. The T cell …
Logic-gated and contextual control of immunotherapy for solid tumors: contrasting multi-specific T cell engagers and CAR-T cell therapies
O Nolan-Stevaux, R Smith - Frontiers in Immunology, 2024 - frontiersin.org
CAR-T cell and T cell engager therapies have demonstrated transformational efficacy
against hematological malignancies, but achieving efficacy in solid tumors has been more …
against hematological malignancies, but achieving efficacy in solid tumors has been more …
Prognostic significance of pyrimidine metabolism-related genes as risk biomarkers in hepatocellular carcinoma
J Lu, L Shi, C Zhang, F Zhang, M Cai - Journal of Chemotherapy, 2024 - Taylor & Francis
Hepatocellular carcinoma (HCC), as a malignancy derived from liver tissue, is typically
associated with poor prognosis. Increasing evidence suggests a connection between …
associated with poor prognosis. Increasing evidence suggests a connection between …